The duration of anticoagulant treatment after a first venous thromboembolism (VTE)
depends on the risk of a VTE recurrence, which is mostly determined by the presence,
type, persistence, and severity of VTE provoking factors [
[1]
,
[2]
]. In particular, if a major provoking factor persists over time, i.e. as it is often
the case for cancer and cancer treatment, an indefinite anticoagulant treatment is
usually considered in the absence of active bleeding or severe bleeding risk factors.
Vice versa, if the VTE provoking risk factor is transient, for instance a major surgical
intervention or trauma, anticoagulation can be discontinued after a standard short
3-month course of anticoagulation, as the risk of recurrence is deemed to be minimal.- Konstantinides S.V.
- Meyer G.
- Becattini C.
- et al.
ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed
in collaboration with the European Respiratory Society (ERS): the Task Force for the
diagnosis and management of acute pulmonary embolism of the European Society of Cardiology
(ESC).
Eur Respir J. 2019; 54 (2019)
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest. 2016; 149: 315-352
- ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).Eur Respir J. 2019; 54 (2019)
- External validation of the DASH prediction rule: a retrospective cohort study.J Thromb Haemost. 2017; 15: 1963-1970
- Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.Circulation. 2010; 121: 1630-1636
- Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.BMJ. 2017; 356: 1065
- Predicting recurrence after a first unprovoked venous thromboembolism: retrospective validation of the DAMOVES score.Eur J Intern Med. 2017; 41: e15-ee6
- External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.Thromb Haemost. 2017; 117: 1164-1170
- How I assess and manage the risk of bleeding in patients treated for venous thromboembolism.Blood. 2020; 135: 724-734
- Treatment of venous thromboembolism with new anticoagulant agents.J Am Coll Cardiol. 2016; 67: 1941-1955
- Pulmonary embolism.Nat Rev Dis Primers. 2018; 4: 18028
- A Test in Context: D-dimer.J Am Coll Cardiol. 2017; 70: 2411-2420
- Fibrin D-dimer concentration, deep vein thrombosis symptom duration, and venous thrombus volume.Angiology. 2011; 62: 253-256
- D-dimer at venous thrombosis diagnosis is associated with risk of recurrence.J Thromb Haemost. 2017; 15: 917-924
- D-dimer measured at diagnosis of venous thromboembolism is associated with risk of major bleeding.TH Open. 2019; 3: e77-e84
- Diagnostic accuracy of D-Dimer testing for recurrent venous thromboembolism: A systematic review with meta-analysis. VTE recurrence and D-dimer.Eur J Intern Med. 2021; https://doi.org/10.1016/j.ejim.2021.04.004
- Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.J Thromb Haemost. 2016; 14: 1480-1483
- Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting.J Thromb Haemost. 2010; 8: 2313-2315
- "HERDOO2" clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any D-Dimer?.Thromb Res. 2018; 169: 82-86
Article info
Publication history
Published online: May 26, 2021
Accepted:
May 5,
2021
Received:
April 29,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
